Lethal Outcomes in Shanghai Reveal Deep Cracks in Gene-Editing Oversight
A child's death following a brain-targeted base-editing procedure has exposed systemic failures in regulating high-risk genetic experiments. Despite toxic results in animal trials, researchers proceeded with a personalized therapy that ultimately proved fatal.
In March 2025, a six-year-old girl diagnosed with Snijders Blok-Campeau syndrome died after receiving an unproven base-editing therapy. The procedure, believed to be a global first for brain-targeted gene correction, has triggered a joint investigation by Science and Retraction Watch. The findings indicate that the experimental trial bypassed rigorous national oversight, highlighting persistent gaps in how China enforces its scientific regulations.
A Risky Intervention for a Non-Fatal Condition
The patient suffered from a rare neurodevelopmental disorder caused by a mutation in the CHD3 gene. While the condition impairs intellectual growth, it is typically not life-threatening. Despite this, neuroscientist Zilong Qiu of Shanghai Jiao Tong University led an effort to develop a personalized treatment using base-editing technology. Developed in 2016 by David Liu at the Broad Institute, base-editing is designed to swap DNA letters without the double-strand breaks characteristic of traditional CRISPR-Cas9, theoretically reducing unintended mutations.
However, the delivery method introduced significant peril. To reach the brain, the team used high doses of adeno-associated viruses (AAVs). Independent experts have since flagged that preclinical data was alarming: toxicology studies in monkeys revealed liver injury across all subjects and kidney damage in one. Ignoring these indicators, the team injected the therapy into the child’s cerebrospinal fluid on March 24, 2025. The girl developed a fever and acute kidney failure shortly after, dying within a week. An internal hospital review later confirmed the cause of death as thrombotic microangiopathy, a known risk of high-dose AAV administration.
Regulatory Bypasses and Hidden Failures
The investigation reveals a troubling lack of transparency and an absence of federal scrutiny. Because the project was categorized as an investigator-initiated trial at Shanghai's Xinhua Hospital, it did not undergo review by the National Medical Products Administration. Furthermore, the financial burden fell heavily on the family, who contributed approximately $860,000 through personal savings and loans.
- Neither the hospital nor the researchers publicly disclosed the fatality when it occurred.
- Local health officials eventually fined the hospital for registration and oversight lapses but declined to sanction Dr. Qiu.
- A related paper published in the journal Nature failed to mention the patient's death or the regulatory irregularities, information the journal stated would have impacted the editorial process.
A Pattern of Ethical Strains
This incident mirrors the 2018 scandal involving He Jiankui, whose unauthorized embryo editing led to a three-year prison sentence and a supposed tightening of Chinese law. Yet, this recent tragedy suggests that the divide between legislative intent and laboratory practice remains wide. The case also echoes the high-pressure environment surrounding rare disease research globally, such as the effort in India to treat Uditi Saraf for FENIB. While the Indian team faced similar technical hurdles and time constraints, they operated under a more cautious regulatory framework, and their patient passed away before the experimental therapy could be administered.
The death in Shanghai serves as a grim warning about the rush to apply "first-in-human" interventions. Critics argue that the case reflects a dangerous combination of societal discomfort with disability and a blind faith in technological solutions that can override basic safety protocols.
Source: The Hindu — Home
